Novartis AG Form 6-K Summary: Third Quarter 2003 Results
Business Context and Reporting Period
This Form 6-K, dated October 20, 2003, reports the unaudited financial results for Novartis AG for the third quarter and the first nine months ended September 30, 2003. The company, headquartered in Basel, Switzerland, operates primarily in Pharmaceuticals and Consumer Health. The reporting period highlights double-digit sales growth driven by strong performance in cardiovascular and oncology franchises, as well as significant expansion in the Sandoz generics business.
Key Financial Metrics
| Metric (USD millions) | 9M 2003 | 9M 2002 | % Change (USD) | Q3 2003 | Q3 2002 | % Change (USD) |
|---|---|---|---|---|---|---|
| Group Sales | 18,134 | 15,308 | 18% | 6,210 | 5,373 | 16% |
| Pharmaceuticals Sales | 11,641 | 9,896 | 18% | 4,041 | 3,451 | 17% |
| Consumer Health Sales | 6,493 | 5,245 | 24% | 2,169 | 1,866 | 16% |
| Operating Income | 4,283 | 3,738 | 15% | 1,469 | 1,320 | 11% |
| Operating Margin | 23.6% | 24.4% | -0.8 pts | 23.7% | 24.6% | -0.9 pts |
| Net Income | 3,656 | 3,538 | 3% | 1,277 | 1,188 | 7% |
| Free Cash Flow | 2,184 | 1,324 | 65% | 1,527 | 1,066 | 43% |
| Basic EPS (USD) | 1.48 | 1.40 | 6% | 0.52 | 0.48 | 8% |
Liquidity and Debt: As of September 30, 2003, total liquidity (cash, equivalents, and marketable securities) was USD 11.9 billion. Net liquidity stood at USD 6.2 billion. Total financial debts remained stable, with a debt-to-equity ratio of 0.20:1. The company maintains a AAA credit rating from Standard & Poor's and Moody's.
Material Changes vs. Prior Period
- Sales Growth Drivers: Group sales grew 18% in USD (11% in local currencies). Volume expansion contributed 8 percentage points, acquisitions 2 percentage points, price increases 1 percentage point, and currency translation 7 percentage points.
- Pharmaceuticals Performance: Sales rose 18%, outpacing the global market. Key drivers included Diovan (+49%), Gleevec/Glivec (+91%), and Zometa (+104%). The cardiovascular and oncology franchises were the primary growth engines.
- Consumer Health Performance: Sales increased 24%, heavily driven by Sandoz (Generics), which posted 67% growth due to the Lek acquisition and US retail expansion. OTC, Medical Nutrition, and CIBA Vision also delivered double-digit growth.
- Profitability: Operating income grew 15% despite a 31% increase in R&D investments (now 15% of sales). Operating margins declined slightly due to higher R&D and General & Administration expenses, including write-downs of biotech investments.
- Non-Operating Items: Net income growth (3%) lagged operating income growth due to a significant reduction in non-operating income from associated companies. Specifically, Novartis recorded a USD 269 million pre-tax loss related to its stake in Roche Holding AG, reflecting Roche's 2002 unexpected loss booked in 2003.
Guidance, Outlook, and Risks
Outlook: Management expects superior short- to mid-term sales growth in the high-single to low-double digit percent range in local currencies. Full-year operating and net income are projected to exceed 2002 levels. However, operating margins are expected to be slightly reduced in 2003 and 2004 as R&D investments increase over-proportionately to sales to sustain innovation.
Key Developments:
- Approvals: US launches for Xolair (asthma) and Stalevo (Parkinson's); European approvals for Certican and Prexige; US approval for Trileptal monotherapy in children.
- Acquisitions: Completed acquisition of 51% of Idenix Pharmaceuticals (USD 255 million initial payment) and Enablex from Pfizer (up to USD 225 million).
- Share Repurchases: 16.51 million shares repurchased in the first nine months for approximately USD 627 million.
Risks and Contingencies:
- Regulatory and Clinical: Risks include unexpected clinical trial results, regulatory delays, and government pricing pressures.
- Accounting Adjustments: The filing notes significant differences between IFRS and US GAAP, particularly regarding purchase accounting, goodwill amortization, and in-process R&D, which reduced US GAAP net income to USD 2.7 billion for the nine-month period.
- Associated Companies: Continued volatility in earnings from associated companies, specifically Roche Holding AG.
Investor Verification Checklist
- Currency Impact: Verify the extent to which the 18% sales growth is driven by the strong USD (7 percentage points) versus organic volume growth (8 percentage points).
- Roche Exposure: Confirm the ongoing impact of the Roche Holding AG loss on future non-operating income and the stability of the associated company portfolio.
- R&D Efficiency: Monitor the trajectory of R&D spending (up 31%) against future pipeline approvals to ensure the investment translates into revenue growth.
- US GAAP Reconciliation: Review the reconciliation of IFRS to US GAAP net income, noting the USD 941 million difference for the nine-month period due to accounting adjustments.
- Sandoz Integration: Assess the sustainability of Sandoz's 67% growth rate following the Lek acquisition and US generic launches.